Tags : Hold

Novartis Reports FDA’s Hold on P-I/II Intrathecal Study Evaluating Zolgensma/AVXS-101

Shots: The partial hold on clinical study for intrathecal administration of AVXS-101 follows the findings of the pre-clinical study demonstrated dorsal root ganglia (DRG) mononuclear cell inflammation accompanied by neuronal cell body degeneration or loss The partial hold does not have any impact on marketed Zolgensma or AVXS-101 (IV) clinical studies and will remain available […]Read More